炎症性肠病与慢性肾病风险增加相关且风险随年龄降低
一项回顾性队列研究纳入17,807例IBD患者和63,466例非IBD对照,发现IBD与16-77岁患者发生慢性肾病(CKD)相关,且调整后风险比随年龄增长单调下降,从16岁的7.88降至77岁的1.13;常用非生物制剂未与eGFR降低相关。
要点
- IBD患者发生CKD的风险增加,年轻患者风险最高。
- 5-氨基水杨酸或甲氨蝶呤与eGFR变化无关。
- 硫唑嘌呤与eGFR轻度升高相关(0.32 mL/min/1.73 m2)。
核心结论
- IBD与CKD风险增加相关,且风险比随年龄增长而降低。
- 常用非生物制剂(5-ASA、硫唑嘌呤、甲氨蝶呤)未与eGFR降低相关。
研究设计与样本
- 基于健康改善网络(THIN)的回顾性队列研究。
- IBD患者17,807例,按年龄、性别和诊所匹配非IBD个体63,466例。
主要发现
- 调整CKD常见危险因素后,IBD与16-77岁患者发生CKD相关。
- 调整后风险比随年龄增长单调下降,16岁时为7.88(95% CI 2.56-24.19),77岁时为1.13(95% CI 1.01-1.25)。
- 纵向分析中,5-ASA或甲氨蝶呤暴露与eGFR变化无关。
- 硫唑嘌呤与eGFR轻度升高相关(0.32 mL/min/1.73 m2;95% CI 0.16-0.48)。
关键数值与推荐
- CKD定义为3至5D期。
- 调整后风险比:16岁7.88(95% CI 2.56-24.19),77岁1.13(95% CI 1.01-1.25)。
- 硫唑嘌呤与eGFR变化:0.32 mL/min/1.73 m2(95% CI 0.16-0.48)。
临床怎么用
- 对IBD患者,尤其是年轻患者,应关注CKD风险并监测肾功能。
- 常用非生物制剂(5-ASA、甲氨蝶呤)不增加eGFR下降风险。
局限性
- 回顾性队列研究设计。
- 使用健康改善网络(THIN)数据,可能存在数据库相关偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is not clear what factors affect risk of chronic kidney disease (CKD) in patients with inflammatory bowel disease (IBD); increased risk has been inconsistently associated with use of 5-aminosalicylates (5-ASAs). We aimed to calculate the relative hazard of CKD among patients with IBD, adjusted for CKD risk factors, and to determine whether IBD medications are associated with change in estimated glomerular filtration rate (eGFR). METHODS: We performed a retrospective cohort study of data from The Health Improvement Network. Patients with IBD (n = 17,807) were matched for age, sex, and practice to individuals without IBD (n = 63,466). The relative hazard of CKD, stages 3 through 5D, in patients with IBD was calculated using a Cox proportional hazards model adjusted for common CKD risk factors. We also evaluated the association of 5-ASAs, azathioprine, and methotrexate with change in eGFR using a longitudinal model. RESULTS: After we controlled for risk factors associated with CKD, we found IBD to be associated with development of CKD in patients 16-77 years old. As patient age increased, the adjusted hazard ratio for CKD decreased monotonically, from 7.88 (95% CI, 2.56-24.19) at age 16 to 1.13 (95% CI, 1.01-1.25) at age 77. In the longitudinal analysis, exposure to 5-ASAs or methotrexate was not associated with change in eGFR, whereas azathioprine was associated with a slightly higher eGFR (0.32 mL/min/1.73 m2; 95% CI, 0.16-0.48). CONCLUSIONS: In a retrospective study of more than 80,000 persons, we found that IBD is associated with increased risk of CKD, and the hazard ratio is highest among younger patients. Commonly used non-biologic therapeutic agents were not associated with lower eGFR.
引用
- Vajravelu RK, Copelovitch L, Osterman MT, et al. Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. Clin Gastroenterol Hepatol. 2019. PMID: 31683056. doi:10.1016/j.cgh.2019.10.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。